287 related articles for article (PubMed ID: 20399790)
61. Immunopathogenesis of severe acute respiratory disease in Zaire ebolavirus-infected pigs.
Nfon CK; Leung A; Smith G; Embury-Hyatt C; Kobinger G; Weingartl HM
PLoS One; 2013; 8(4):e61904. PubMed ID: 23626748
[TBL] [Abstract][Full Text] [Related]
62. Ebola virus VP35 blocks stress granule assembly.
Le Sage V; Cinti A; McCarthy S; Amorim R; Rao S; Daino GL; Tramontano E; Branch DR; Mouland AJ
Virology; 2017 Feb; 502():73-83. PubMed ID: 28013103
[TBL] [Abstract][Full Text] [Related]
63. Insights into Ebola Virus VP35 and VP24 Interferon Inhibitory Functions and their Initial Exploitation as Drug Targets.
Fanunza E; Frau A; Corona A; Tramontano E
Infect Disord Drug Targets; 2019; 19(4):362-374. PubMed ID: 30468131
[TBL] [Abstract][Full Text] [Related]
64. Ebola virus VP35 interaction with dynein LC8 regulates viral RNA synthesis.
Luthra P; Jordan DS; Leung DW; Amarasinghe GK; Basler CF
J Virol; 2015 May; 89(9):5148-53. PubMed ID: 25741013
[TBL] [Abstract][Full Text] [Related]
65. The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide.
Jin H; Yan Z; Prabhakar BS; Feng Z; Ma Y; Verpooten D; Ganesh B; He B
J Gen Virol; 2010 Feb; 91(Pt 2):352-61. PubMed ID: 19828757
[TBL] [Abstract][Full Text] [Related]
66. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.
Geisbert TW; Lee AC; Robbins M; Geisbert JB; Honko AN; Sood V; Johnson JC; de Jong S; Tavakoli I; Judge A; Hensley LE; Maclachlan I
Lancet; 2010 May; 375(9729):1896-905. PubMed ID: 20511019
[TBL] [Abstract][Full Text] [Related]
67. Purification and functional characterization of the full length recombinant Ebola virus VP35 protein expressed in E. coli.
Zinzula L; Esposito F; Mühlberger E; Trunschke M; Conrad D; Piano D; Tramontano E
Protein Expr Purif; 2009 Jul; 66(1):113-9. PubMed ID: 19233284
[TBL] [Abstract][Full Text] [Related]
68. The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo.
Groseth A; Marzi A; Hoenen T; Herwig A; Gardner D; Becker S; Ebihara H; Feldmann H
PLoS Pathog; 2012; 8(8):e1002847. PubMed ID: 22876185
[TBL] [Abstract][Full Text] [Related]
69. Exploring interaction mechanisms of the inhibitor binding to the VP35 IID region of Ebola virus by all atom molecular dynamics simulation method.
Zhang YJ; Ding JN; Feng TT; Han JG
Proteins; 2015 Dec; 83(12):2263-78. PubMed ID: 26466951
[TBL] [Abstract][Full Text] [Related]
70. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.
Hartman AL; Towner JS; Nichol ST
Virology; 2004 Oct; 328(2):177-84. PubMed ID: 15464838
[TBL] [Abstract][Full Text] [Related]
71. Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells.
Ilinykh PA; Lubaki NM; Widen SG; Renn LA; Theisen TC; Rabin RL; Wood TG; Bukreyev A
J Virol; 2015 Aug; 89(15):7567-83. PubMed ID: 25972536
[TBL] [Abstract][Full Text] [Related]
72. VP24-Karyopherin Alpha Binding Affinities Differ between Ebolavirus Species, Influencing Interferon Inhibition and VP24 Stability.
Schwarz TM; Edwards MR; Diederichs A; Alinger JB; Leung DW; Amarasinghe GK; Basler CF
J Virol; 2017 Feb; 91(4):. PubMed ID: 27974555
[TBL] [Abstract][Full Text] [Related]
73. Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence.
Kash JC; Mühlberger E; Carter V; Grosch M; Perwitasari O; Proll SC; Thomas MJ; Weber F; Klenk HD; Katze MG
J Virol; 2006 Mar; 80(6):3009-20. PubMed ID: 16501110
[TBL] [Abstract][Full Text] [Related]
74. The importance of the NP: VP35 ratio in Ebola virus nucleocapsid formation.
Noda T; Kolesnikova L; Becker S; Kawaoka Y
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S878-83. PubMed ID: 21987764
[TBL] [Abstract][Full Text] [Related]
75. Involvement of viral envelope GP2 in Ebola virus entry into cells expressing the macrophage galactose-type C-type lectin.
Usami K; Matsuno K; Igarashi M; Denda-Nagai K; Takada A; Irimura T
Biochem Biophys Res Commun; 2011 Apr; 407(1):74-8. PubMed ID: 21362405
[TBL] [Abstract][Full Text] [Related]
76. Predictive and comparative analysis of Ebolavirus proteins.
Cong Q; Pei J; Grishin NV
Cell Cycle; 2015; 14(17):2785-97. PubMed ID: 26158395
[TBL] [Abstract][Full Text] [Related]
77. A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge.
Woolsey C; Menicucci AR; Cross RW; Luthra P; Agans KN; Borisevich V; Geisbert JB; Mire CE; Fenton KA; Jankeel A; Anand S; Ebihara H; Geisbert TW; Messaoudi I; Basler CF
Cell Rep; 2019 Sep; 28(12):3032-3046.e6. PubMed ID: 31533029
[TBL] [Abstract][Full Text] [Related]
78. Discovery of swine as a host for the Reston ebolavirus.
Barrette RW; Metwally SA; Rowland JM; Xu L; Zaki SR; Nichol ST; Rollin PE; Towner JS; Shieh WJ; Batten B; Sealy TK; Carrillo C; Moran KE; Bracht AJ; Mayr GA; Sirios-Cruz M; Catbagan DP; Lautner EA; Ksiazek TG; White WR; McIntosh MT
Science; 2009 Jul; 325(5937):204-6. PubMed ID: 19590002
[TBL] [Abstract][Full Text] [Related]
79. The Ebola Viral Protein 35 N-Terminus Is a Parallel Tetramer.
Chanthamontri CK; Jordan DS; Wang W; Wu C; Lin Y; Brett TJ; Gross ML; Leung DW
Biochemistry; 2019 Feb; 58(6):657-664. PubMed ID: 30592210
[TBL] [Abstract][Full Text] [Related]
80. The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses.
Lubaki NM; Younan P; Santos RI; Meyer M; Iampietro M; Koup RA; Bukreyev A
PLoS Pathog; 2016 Dec; 12(12):e1006031. PubMed ID: 27930745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
